MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that the Company has received 510(k) FDA clearance for the newest generation of its personal exoskeleton device, the ReWalk 7. The seventh generation of the ReWalk, a wearable exoskeleton that allows individuals with spinal cord injury (SCI) to stand and walk again, includes a number of new features, as well as enhancements and upgrades. "FDA clearance is a major milestone for our Company and for the industry,"

Record quarterly and annual revenue of $7.5M and $25.7M, respectively Continued strong growth in U.S. pipeline of ReWalk opportunities with over 110 qualified leads in process Strategic shift towards profitability: 2025 Sustainable Growth Plan focuses on growth of core product lines with a streamlined cost structure and reduced operating loss MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months and full year ended Decem

CorLife to become the exclusive distributor of the ReWalk Personal Exoskeleton for individuals with Workers' Compensation claims Partnership expected to enable Lifeward to achieve greater growth and penetration into the Workers' Compensation market MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel and GREEN BAY, Wis., March 06, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward") a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, and CorLife, LLC., ("CorLife") a division of Numotion, the nation's leading and largest provider of products and services that provide mobility

Laidlaw initiated coverage of Lifeward with a rating of Buy and set a new price target of $10.00

HC Wainwright reiterated coverage of ReWalk Robotics with a rating of Buy and set a new price target of $3.50 from $2.50 previously

HC Wainwright & Co. reiterated coverage of ReWalk Robotics with a rating of Buy and set a new price target of $3.50 from $2.50 previously

4 - Lifeward Ltd. (0001607962) (Issuer)

4 - Lifeward Ltd. (0001607962) (Issuer)

4 - Lifeward Ltd. (0001607962) (Issuer)

4 - Lifeward Ltd. (0001607962) (Issuer)

4 - Lifeward Ltd. (0001607962) (Issuer)

4 - Lifeward Ltd. (0001607962) (Issuer)

8-K - Lifeward Ltd. (0001607962) (Filer)

424B5 - Lifeward Ltd. (0001607962) (Filer)

10-K - Lifeward Ltd. (0001607962) (Filer)

MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions in physical rehabilitation and recovery, announced the Board of Directors has approved the appointment of Robert J. Marshall Jr. as a new director effective November 2, 2024. As part of his duties as a director, Mr. Marshall will serve as Chairman of the Audit Committee. Mr. Marshall has had a long and accomplished finance career in the medical device industry. Currently, Mr. Marshall serves as the Chief Financial Officer and Treasurer of Lantheus Holdings, Inc., a publicly traded radiopharmaceut

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that Dr. Keith E. Tansey, MD, PhD, will be joining its Medical Affairs team as a consultant in the role of Director, Clinical Research. Dr. Tansey's responsibilities will include the development and stewardship of Lifeward's clinical research program, the advancement of key opinion leader opportunities, and iden

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that Jeff Dykan, current Chairman of the Lifeward Board of Directors, will retire from his role and will not stand for reelection effective at the 2024 Annual Meeting of Shareholders. Joseph Turk, who has served on Lifeward's Board since 2022, has been appointed as the incoming Chairman and will assume the role f

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and fiscal year-end financial results before the markets open on Friday, March 7, 2025. Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-3

CEO Larry Jasinski to Retire Company Begins Search for New Leader to Drive Next Phase of Growth Company Provides Preliminary Full-Year 2024 Revenue Reschedules Virtual Investor Event Until Later in 2025 After Hiring of New CEO MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Larry Jasinski, the Company's Chief Executive Officer, will step down after a distinguished 13-year career at the Company. Mr. Jasinski will continue to serve in his existin

Second consecutive quarter of 20 ReWalk systems sold Robust growth in U.S. ReWalk pipeline of approximately 70 qualified leads for potential claim submission with Medicare and other U.S. payors MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions in physical rehabilitation and recovery, today announced its financial results for the three months and nine months ended September 30, 2024. Recent Highlights and Milestones for Lifeward Lifeward initiated actions to further streamline its U.S. operations including closing two U.S. facili

SC 13D/A - ReWalk Robotics Ltd. (0001607962) (Subject)

SC 13D/A - ReWalk Robotics Ltd. (0001607962) (Subject)

SC 13D - ReWalk Robotics Ltd. (0001607962) (Subject)